Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viprinex in sudden sensorineural hearing loss
NCT01621256Phase 2Completed
- Sponsor
- Nordmark Pharma
- Start
- May 2013
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ancrod in sudden sensorineural hearing loss (SSHL) (2 arms), sponsored by Nordmark Pharma. Primary endpoint: Pure Tone Audiogram at 8 days. Started May 2013; status: completed.
02
Drugs
ancrod
03
Conditions
sudden sensorineural hearing loss (SSHL)
Beyond the preview
Go deeper on NCT01621256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621256.